PDE1C — Phosphodiesterase 1C

PDE1C — Phosphodiesterase 1C

Introduction

Pde1C — Phosphodiesterase 1C is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@soderling2001]
<table> [@pde2010]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Phosphodiesterase 1C</th></tr> [@amyloidbeta2009]
<tr><td><strong>Gene Symbol</strong></td><td>PDE1C</td></tr> [@pde2013]
<tr><td><strong>Full Name</strong></td><td>Phosphodiesterase 1C</td></tr> [@calciumcalmodulin2000]
<tr><td><strong>Chromosome</strong></td><td>2p21</td></tr> [@pde2015]
<tr><td><strong>NCBI Gene ID</strong></td><td>[5156](https://www.ncbi.nlm.nih.gov/gene/5156)</td></tr> [@pdec2009]
<tr><td><strong>OMIM</strong></td><td>618033</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000154678</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q14139](https://www.uniprot.org/uniprot/Q14139)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Cancer</td></tr>
</table>
</div>

Overview

...

PDE1C — Phosphodiesterase 1C

Introduction

Pde1C — Phosphodiesterase 1C is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@soderling2001]
<table> [@pde2010]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Phosphodiesterase 1C</th></tr> [@amyloidbeta2009]
<tr><td><strong>Gene Symbol</strong></td><td>PDE1C</td></tr> [@pde2013]
<tr><td><strong>Full Name</strong></td><td>Phosphodiesterase 1C</td></tr> [@calciumcalmodulin2000]
<tr><td><strong>Chromosome</strong></td><td>2p21</td></tr> [@pde2015]
<tr><td><strong>NCBI Gene ID</strong></td><td>[5156](https://www.ncbi.nlm.nih.gov/gene/5156)</td></tr> [@pdec2009]
<tr><td><strong>OMIM</strong></td><td>618033</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000154678</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q14139](https://www.uniprot.org/uniprot/Q14139)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Cancer</td></tr>
</table>
</div>

Overview

PDE1C (Phosphodiesterase 1C) is a calcium/calmodulin-dependent phosphodiesterase that hydrolyzes both [cAMP](/entities/cyclic-amp) and [cGMP](/entities/cyclic-gmp), serving as a critical regulator of cyclic nucleotide signaling in cells. The gene is located on chromosome 2p21 and encodes a protein of approximately 87 kDa. PDE1C is highly expressed in the [brain](/brain-regions/brain-overview), particularly in the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and [cerebellum](/brain-regions/cerebellum), where it plays essential roles in [synaptic plasticity](/mechanisms/synaptic-plasticity), memory formation, and neuronal survival.

PDE1C is unique among the PDE family in its dual-substrate specificity and strong brain expression, making it a key link between [calcium signaling](/mechanisms/calcium-signaling-neurodegeneration) and cyclic nucleotide pathways. This positioning as a signaling integrator has made PDE1C a focal point for understanding neurodegenerative disease mechanisms and developing therapeutic interventions.

Gene Structure and Expression

Genomic Organization

The PDE1C gene spans approximately 41 kb and contains 26 exons. Multiple transcription initiation sites generate alternatively spliced variants with distinct tissue distribution patterns. The promoter region contains response elements for several transcription factors, including CREB (cAMP Response Element-Binding Protein), allowing activity-dependent regulation.

Tissue Distribution

PDE1C exhibits a distinctive expression pattern:

• Brain: Highest expression in the [cerebral cortex](/brain-regions/cerebral-cortex), [hippocampus](/brain-regions/hippocampus), [basal ganglia](/brain-regions/basal-ganglia), and [cerebellum](/brain-regions/cerebellum)
• Peripheral tissues: Expressed in vascular smooth muscle, platelets, and testis
• Cell types: Expressed in [neurons](/cell-types/neurons), [astrocytes](/cell-types/astrocytes), and [microglia](/cell-types/microglia)

Cell-Type Specific Functions

In [neurons](/cell-types/neurons), PDE1C localizes to both dendritic and somatic compartments, where it regulates:

• Synaptic vesicle cycling
• Ion channel function
• Gene transcription via CREB

In [astrocytes](/cell-types/astrocytes), PDE1C modulates:

• Glutamate uptake
• Calcium wave propagation
• Metabolic support for [neurons](/entities/neurons)

Protein Structure and Function

Domain Architecture

The PDE1C protein contains several distinct functional domains:

N-terminal regulatory domain: Contains multiple calmodulin-binding motifs

EF-hand motifs: Two calcium-binding motifs that sense intracellular calcium changes

Catalytic domain: Contains the conserved PDE signature sequence for hydrolysis

Dimerization interface: Enables formation of functional homodimers

Enzymatic Activity

PDE1C catalyzes the hydrolysis of:

• [cAMP](/entities/cyclic-amp): The primary substrate in most brain regions
• [cGMP](/entities/cyclic-gmp): Important for nitric oxide signaling

The enzyme is uniquely activated by the calcium/calmodulin complex, allowing rapid响应 to changes in intracellular calcium concentrations. This makes PDE1C a key integrator of calcium and cyclic nucleotide signaling pathways.

Role in Neuronal Signaling

Calcium-Calmodulin Activation

PDE1C provides a critical link between [calcium signaling](/mechanisms/calcium-signaling-neurodegeneration) and cyclic nucleotide pathways:

Calcium influx through voltage-gated channels or NMDA receptors

Calcium binds to calmodulin

Calcium-calmodulin complex activates PDE1C

Activated PDE1C hydrolyzes cAMP/cGMP

Reduced PKA/PKG activity modulates ion channel function and gene transcription

Synaptic Plasticity

PDE1C plays a crucial role in [synaptic plasticity](/mechanisms/synaptic-plasticity):

• [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP): Regulates cAMP levels necessary for LTP induction in hippocampal neurons
• Long-term depression (LTD): Modulates actin cytoskeleton remodeling through cAMP/PKA pathways
• Memory consolidation: CREB-mediated gene transcription requires proper cAMP signaling

Neuroprotection

PDE1C activity influences neuronal survival through:

• Regulation of BDNF (Brain-Derived Neurotrophic Factor) expression
• Modulation of mitochondrial function
• Control of antioxidant responses

Disease Associations

Alzheimer's Disease

PDE1C has significant implications for [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis:

| Aspect | Mechanism | Evidence |
|--------|-----------|----------|
| Memory impairment | Elevated PDE1C activity reduces cAMP, impairing synaptic plasticity | Preclinical studies show PDE1 inhibition improves memory |
| [Amyloid-beta](/proteins/amyloid-beta) pathology | Aβ oligomers dysregulate PDE1C-cAMP signaling | Reduced PDE1C activity in AD brain |
| [Tau](/proteins/tau) pathology | cAMP/PKA signaling affects tau phosphorylation | PDE1 inhibitors reduce tau pathology in models |
| Therapeutic potential | PDE1 inhibitors enhance cognitive function | Clinical trials ongoing |

Key mechanisms include:

• Dysregulated cAMP signaling in hippocampal neurons
• Impaired CREB-mediated transcription of synaptic proteins
• Reduced BDNF expression and neurotrophic support

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), PDE1C affects:

• Dopaminergic neuron survival: cAMP dysregulation contributes to neurodegeneration
• Levodopa response: PDE1 activity may modulate dopaminergic therapy efficacy
• Neuroprotection: PDE1 inhibitors protect against MPTP toxicity in models

Huntington's Disease

PDE1C alterations in [Huntington's disease](/diseases/huntington-disease):

• Mutant [huntingtin](/proteins/huntingtin) affects PDE1C expression and localization
• cAMP signaling deficits contribute to synaptic dysfunction
• PDE1 inhibition shows therapeutic promise

Amyotrophic Lateral Sclerosis

In [ALS](/diseases/amyotrophic-lateral-sclerosis):

• Motor neuron cAMP dysregulation
• Astrocyte PDE1C affects neuronal support
• Therapeutic targeting under investigation

Therapeutic Targeting

PDE1 Inhibitors

Several PDE1 inhibitors have been developed for neurological applications:

| Inhibitor | Selectivity | Development Status | Notes |
|-----------|-------------|-------------------|-------|
| Vinpocetine | PDE1 | Approved (cognitive supplement) | Mild PDE1 inhibition |
| IC86340 | PDE1 | Preclinical | Selective for PDE1C |
| KR-36996 | PDE1 | Preclinical | Neuroprotective effects |
| PF-04447943 | PDE1A | Clinical trials | Tested in AD |

Clinical Applications

PDE1C inhibition is being explored for:

• Cognitive enhancement in aging and dementia
• Neuroprotection in Parkinson's disease
• Adjunct therapy in depression
• Treatment of attention disorders

Interactions and Pathways

Signaling Network

PDE1C interacts with multiple signaling pathways:

• Calmodulin: Activation by calcium-calmodulin complex
• [PKA](/proteins/protein-kinase-a): cAMP effector kinase
• [PKG](/proteins/protein-kinase-g): cGMP effector kinase
• CREB: Transcription factor regulated by cAMP/PKA
• BDNF: Neurotrophic factor with cAMP-dependent expression
• Ion channels: Modulation of NMDA, AMPA, and potassium channels

Protein Interactions

PDE1C forms complexes with:

• Calmodulin (activation-dependent binding)
• 14-3-3 proteins (signaling scaffolding)
• Spinophilin ( dendritic targeting)
• PDE10A (possible cross-talk)

Animal Models

Knockout Studies

Pde1c knockout mice show:

• Elevated cAMP in brain tissue
• Enhanced hippocampal LTP
• Improved spatial memory
• Normal development and viability

Transgenic Models

Mouse models overexpressing PDE1C exhibit:

• Impaired memory consolidation
• Reduced hippocampal synaptic plasticity
• Age-dependent cognitive decline

Clinical Significance

Genetic Variants

PDE1C polymorphisms have been associated with:

• Cognitive performance in elderly populations
• Response to [cholinesterase inhibitors](/entities/cholinesterase-inhibitors) in AD
• Parkinson's disease susceptibility

Biomarker Potential

PDE1C expression/activity may serve as:

• Disease progression marker in AD
• Therapeutic response indicator
• Target engagement biomarker for PDE1 inhibitors

Research Directions

Current research focuses on:

• Developing brain-penetrant PDE1 inhibitors
• Understanding isoform-specific functions
• Identifying biomarkers for patient selection
• Combination therapies with existing treatments

See Also

• [PDE1C Protein](/proteins/pde1c-protein)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [cAMP Signaling](/mechanisms/camp-dependent-signaling)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Calcium Signaling](/mechanisms/calcium-signaling-neurodegeneration)

Background

The study of Pde1C — Phosphodiesterase 1C has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

[Hetman JM, et al., (2000). Calcium/calmodulin-dependent phosphodiesterases in the CNS. J Neurosci Res (2000)](https://pubmed.ncbi.nlm.nih.gov/11145981/)

[Unknown, Soderling SH, Beavers JS (2001). The calcium and calmodulin-dependent phosphodiesterase family. FEBS Lett (2001)](https://pubmed.ncbi.nlm.nih.gov/11513814/)

[Unknown, PDE1 inhibition improves memory in Alzheimer's disease models. J Neurosci (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20452377/)

[Unknown, Amyloid-beta effects on phosphodiesterase signaling in neurons. J Biol Chem (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19158546/)

[Unknown, PDE1 in dopaminergic neuron function and Parkinson's disease. Neurobiol Aging (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23474447/)

[Unknown, Calcium-calmodulin phosphodiesterases in the brain. Prog Neuropsychopharmacol Biol Psychiatry (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10517883/)

[Unknown, PDE1 inhibitors as therapeutic agents for neurodegenerative diseases. CNS Drugs (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25880023/)

[Unknown, PDE1C structure and function. Handb Exp Pharmacol (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19374376/)